Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BE-101 (BiomEdit)
- Development stage
- Preclinical
- Lead developer
- Be Biopharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**BE-101** is BiomEdit's engineered probiotic vectored antibody biologic for preventing mortality associated with necrotic enteritis in broiler chickens. The investigational veterinary product uses genetically engineered commensal *Limosilactobacillus reuteri* probiotic vectors to deliver toxin-neutralizing antibody fragments locally in the gastrointestinal tract. Its intended mechanism is neutralization of key *Clostridium perfringens* virulence toxins, including NetB and alpha toxin, thereby reducing toxin-mediated intestinal injury, mortality, and production losses associated with necrotic enteritis. BiomEdit plans to commercialize the product as **Optavant** after full licensure; as of August 2026, it remains in the final stages of the USDA conditional-licensure process.
- Brand names
- Optavant
02
Targets
NetB (Necrotic enteritis toxin B)Hla (Staphylococcus aureus alpha toxin)
Beyond the preview
Go deeper on BE-101 (BiomEdit).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BE-101 (BiomEdit).